Colorectal Cancer Update
A Continuing Medical Education Audio Series
STATEMENT OF NEED / TARGET AUDIENCE
Colorectal cancer is among the most common cancers in the United States, and the arena of colorectal cancer
treatment continues to evolve. Published results from ongoing clinical trials lead to the emergence of new therapeutic
agents and regimens and changes in indications, doses and schedules for existing treatments. In order to
offer optimal patient care — including the option of clinical trial participation — the practicing medical oncologist
must be well informed of these advances.
To bridge the gap between research and patient care, Colorectal Cancer Update utilizes one-on-one
discussions with leading oncology investigators. By providing access to the latest research developments and
expert perspectives, this CME activity assists medical oncologists in the formulation of up-to-date clinical
management strategies.
GLOBAL LEARNING OBJECTIVES
- Critically evaluate the clinical implications of emerging clinical trial data in colorectal cancer treatment, and
incorporate these data into management strategies in the local and advanced disease settings.
- Counsel appropriate patients about the availability of ongoing clinical trials.
- Evaluate the emerging research data on various adjuvant chemotherapy approaches, including the use of
oxaliplatin-containing regimens and the use of capecitabine or intravenous 5-FU, and explain the absolute
risks and benefits of these regimens to patients.
- Evaluate emerging research data on various neoadjuvant radiation therapy/chemotherapy approaches to
rectal cancer and explain the absolute risks and benefits of these regimens to patients.
- Integrate emerging data on biologic therapies into management strategies for patients with advanced
colorectal cancer.
PURPOSE OF THIS ISSUE OF COLORECTAL CANCER UPDATE
The purpose of Issue 3 of Colorectal Cancer Update is to support these global objectives by offering the perspectives
of Drs Venook, Wexner, Willett and Hecht on the integration of emerging clinical research data into the
management of colorectal cancer.
ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide
continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Research To Practice designates this educational activity for a maximum of 3 AMA PRA Category 1 Credit(s)™.
Physicians should only claim credit commensurate with the extent of their participation in the activity.
HOW TO USE THIS CME ACTIVITY
This CME activity contains both audio and print components. To receive credit, the participant should listen to the
CDs, review the monograph and complete the Post-test and Evaluation Form located in the back of this monograph
or on our website. This monograph contains edited comments, clinical trial schemas, graphics and references
that supplement the audio program. ColorectalCancerUpdate.com includes an easy-to-use, interactive version
of this monograph with links to relevant full-text articles, abstracts, trial information and other web resources
indicated here in blue underlined text.
This program is supported by education grants from Genentech BioOncology, Roche Laboratories Inc and Sanofi-Aventis.
